BMS-986278
目录号: PL06751 纯度: ≥99%
CAS No. :2170126-74-4
商品编号 规格 价格 会员价 是否有货 数量
PL06751-5mg 5mg ¥17927.27 请登录
PL06751-10mg 10mg ¥29054.55 请登录
PL06751-50mg 50mg 询价 询价
PL06751-100mg 100mg 询价 询价
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
BMS-986278
英文名称
BMS-986278
英文别名
4UN9AOU6G8;GTPL11798;BMS986278;compound 33 [PMID: 34709814];(1S,3S)-3-((2-Methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid;(1S,3S)-3-[2-methyl-6-[1-methyl-5-[[methyl(propyl)carbamoyl]oxymethyl]triazol-4-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid;Cyclohexanecarboxylic acid, 3-((2-methyl-6-(1-methyl-5-((((methylpropylamino)carbonyl)oxy)me;Unii-4UN9aou6G8
Cas No.
2170126-74-4
分子式
C22H31N5O5
分子量
445.51
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
BMS-986278 是一种有效和具有口服活性的血磷脂酸受体 1 (LPA1) 拮抗剂,对人和小鼠 LPA1 的 Kb 值分别为 6.9 nM 和 4.0 nM。BMS-986278 可用于研究肺纤维化疾病。
生物活性
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K b s of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases.
性状
Solid
IC50 & Target[1][2]
Kb: 6.9 nM (human LPA1), 4.0 nM (mouse LPA1)
体外研究(In Vitro)
BMS-986278 is a high-affinity LPA1 antagonist, with Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1 in CHO cells overexpressing LPA1.
BMS-986278 antagonizes Lysophosphatidic acid (LPA)-stimulated calcium flux in normal human lung fibroblasts, with a Kb of 5.8 nM.
has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
BMS-986278 (0.1-10 mg/kg; a single p.o.) completely inhibits LPA-stimulated systemic histamine release in a concentration-dependent manner in CD1 mice.
BMS-986278 (3-30 mg/kg; p.o. twice daily for 14 d) decreases Bleomycin-induced collagen deposition/lung fibrosis in rats.

Pharmacokinetics of BMS-986278 in preclinical species
plasma clearance ((mL/min)/kg)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Cheng PTW, et, al. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. J Med Chem. 2021 Nov 11;64(21):15549-15581.
溶解度数据
In Vitro: DMSO : 100 mg/mL (224.46 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2